Please assess the completion status of the following clinical trial:

Trial Title: C1-inhibitor in Allergic ASThma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Intermittent to mild asthma according to the Global Initiative for Asthma (GINA) criteria~* Allergy for HDM documented by a positive RAST and a positive skin prick test.~* No clinically significant findings during physical examination and hematological and biochemical screening~* At spirometry FEV1 more than 70% of predicted value~* A PC20 between 0.3 - 9.6 mg/ml (corresponding with increased airway hyperreactivity)~* Able to communicate well with the investigator and to comply with the requirements of the study~* Stable asthma without the use of asthma medication 2 weeks prior to the study day. As documented by the Juniper's Asthma control questionnaire (ACQ) score \< 1,2.~* Written informed consent~* No current smoking for at least 1 year and less than 10 pack years of smoking history~Exclusion Criteria:~* Relevant comorbidity, pregnancy and/or recent surgical procedures.~* A history of smoking within the last 12 months, or regular consumption of greater than three units of alcohol per day~* Exacerbation and/ or the use of asthma medication within 2 weeks before start~* Administration of any investigational drug within 30 days of study initiation~* Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12 weeks of study initiation\]~* History of venous or arterial thromboembolic disease~* History of enhanced bleeding tendency or abnormal clotting test results.~* History of serious drug-related reactions, including hypersensitivity~* Inability to maintain stable without the use of asthma medication 2 weeks before start of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- C1-inhibitor (Type: EXPERIMENTAL): One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
- Saline (Type: PLACEBO_COMPARATOR): One gift of intravenous administration of 0.9% NaCl during one hour.
- Antibiotics (Type: EXPERIMENTAL): broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).

Based on this trial design, predict the completion outcome and termination type (if applicable).